穴位敷贴辅助治疗肺癌术后气虚痰湿型咳嗽的临床观察
##plugins.themes.bootstrap3.article.sidebar##
##plugins.themes.bootstrap3.article.main##
摘要
目的 观察穴位敷贴辅助治疗肺癌术后气虚痰湿型咳嗽的疗效。方法 将 51 例患者按完全随机分组的方法分为治疗组 27 例、对照组 24 例。两组基础治疗均为小青龙汤合四君子汤加减的中药汤剂。治疗组采用穴位敷贴治疗，对照组采用空白穴位敷贴治疗，疗程 14 天。比较两组治疗前、治疗后咳嗽症状变化、咳嗽视觉模拟评分 (visual analogue score,VAS)、外周血清细胞因子水平。结果 治疗 14 天后，治疗组和对照组的有效率分别为 93.6% 和 73.9%，治疗组明显优于对照组（p<0.01）。治疗后，两组VAS评分均有降低，治疗组降低更明显（p<0.001)；治疗后，两组外周血细胞因子白介素-2r（interleukin-2r，IL-2r）、白介素-6（interleukin-6，IL-6）均改善，与治疗前比较差异有统计学差异，治疗组改善更明显（p<0.001）。结论 穴位敷贴辅助治疗肺癌气虚痰湿型咳嗽效果显著，可明显改善肺癌术后咳嗽患者的临床症状，有效提高患者生活质量。
##plugins.themes.bootstrap3.article.details##
参考
Oncology Committee of Chinese Medical Association. Oncology Committee of Chinese Medical Association guidelines for clinical diagnosis and treatment of lung cancer (2021 edition). National Medical Journal of China. 2021;101(23):1725-57. (in Chinese)
National Administration of Traditional Chinese Medicine. Criteria of diagnosis and therapeutic effects of diseases and syndromes in traditional Chinese medicine. Beijing: China Medical Science and Technology Press；2012. (in Chinese)
Chen G. Effects of Shenfu injection on chemotherapy-induced adverse effects and quality of life in patients with advanced non-small cell lung cancer：a systematic review and meta-analysis J Cancer Res Ther. 2018;14(12):S549-55.
Chu XX, Li LY. The role of interleukin in airway inflammation in chronic obstructive pulmonary disease. Journal of Hebei North University (natural science edition). 2014;30(05):110-3. (in Chinese)
Orditura M, Romano C, De Vita F, Galizia G, Lieto E, Infusino S, et al. Behaviour of interleukin-2 serum levels in advanced non-small-cell lung cancer patients: relationship with response to therapy and survival. Cancer Immunol Immunother. 2000;49(10):530-6.
Kuo SH, Chang DB, Lee YC, Lee YT, Luh KT. Tumour-infiltrating lymphocytes in non-small cell lung cancer are activated T lymphocytes. Journal of Asian Pacific Society of Respirology. 1998;3(1):55-9.
Yano T, Yoshino I, Yokoyama H, Fukuyama Y, Takai E, Asoh H, et al. The clinical significance of serum soluble interleukin-2 receptors in lung cancer. Lung Cancer Journal. 1996;15(1):79-84.
Kawashima O, Kamiyoshihara M, Sakata S, Endo K, Saito R, Morishita Y. The clinicopathological significance of preoperative serum-soluble interleukin-2 receptor concentrations in operable non-small-cell lung cancer patients. Ann Surg Oncol. 2000;7(3):239-45.
Yamaji H, Iizasa T, Koh E, Suzuki M, Otsuji M, Chang H, et al. Correlation between interleukin 6 production and tumor proliferation in non-small cell lung cancer. Cancer Immunol. Immunother. 2004;53:786-92.
Koh E, Iizasa T, Yamaji H, Sekine Y, Hiroshima K, Yoshino I, et al. Significance of the correlation between the expression of interleukin 6 and clinical features in patients with non-small cell lung cancer. Int J Surg Pathol. 2012;20(3):233-9.
Kita H, Shiraishi Y, Watanabe K, Suda K, Ohtsuka K, Koshiishi Y, et al. Does postoperative serum interleukin-6 influence early recurrence after curative pulmonary resection of lung cancer?. Ann Thorac Cardiovasc Surg. 2011;17(5):454-60.
Zhou JJ, Qu ZX, Yan SP, Sun F, Whitsett JA, Shapiro SD, et al. Differential roles of STAT3 in the initiation and growth of lung cancer. Oncogene. 2015;34(29):3804-14.
Il’yasova D, Colbert LH, Harris TB, Newman AB, Bauer DC, Satterfield S, et al. Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort. Cancer Epidemiol Biomarkers Prev. 2005;14(10):2413-8.
Qu ZX, Sun F, Zhou JJ, Li LW, Shapiro SD, Xiao GT. Interleukin-6 Prevents the Initiation but enhances the Pprogression of lung cancer. Cancer Res. 2015;75(16):3209-15.
